The triage problem in complaint handling has become increasingly complex, with high-volume product lines generating thousands of records per month from various sources, including call centers, field service reports, and social media. Each record must be assessed to determine if it’s a complaint, requires investigation, or is reportable to the FDA.
Under 21 CFR Part 803, manufacturers must file a Medical Device Report within 30 calendar days of becoming aware of an event that suggests a death, serious injury, or malfunction. Certain events that require remedial action to prevent an unreasonable risk of substantial harm to public health must be reported within five work days. Manual triage struggles to keep up with the volume, leading to backlogs and inconsistencies.
AI-Assisted Triage
AI has emerged as a solution to remove blind spots in manual triage. It can process incoming records, normalize formats, translate foreign-language reports, and suggest initial event codes. This ensures that nothing sits unread, and the regulatory clock starts before the file is opened.
The use of AI also provides memory, allowing it to connect complaints across regions, lots, and time. Pattern detection is where algorithms excel, and it’s exactly what post-market surveillance regulations expect. A cluster that would take a human team a quarter to notice can surface in days.
AI also brings consistency, applying the same logic to every record without getting tired or changing judgment. However, human mistakes and model mistakes fail differently, and the difference matters in complaint handling. When a model misjudges a complaint, the error is systematic and can quietly bury records until someone notices.
Models can also drift as products change, new failure modes appear, and users invent new language to describe them. A model trained on last year’s complaints can be blind to this year’s problem. Reviewers who trust an algorithm’s sorting can weaken their human check, leading to automation bias.
A company using AI for triage must validate the tool before use, defining what it’s allowed to decide, testing it against records with known outcomes, and setting acceptance criteria before it touches live data. The U.S. Food and Drug Administration already inspects AI triage tools under the Quality Management System Regulation, which incorporates ISO 13485:2016. Investigators expect to see validation, monitoring, and an audit trail showing what the model suggested and who owned the decision.
Regulatory Framework
The regulatory framework for AI triage tools already exists, and companies must draw a line between automating work and keeping human judgment. Table 1 shows a line that holds up, with tasks such as intake and format normalization, translation, and initial event coding suggestions being safe to automate with monitoring.
Read Also: Sensors improve healthcare with continuous monitoring
The principle is simple: the algorithm may order the queue, but it must never decide what the items in the queue are. Monitoring is the second half of a defensible program, and companies should sample the model’s output, track its performance, and define retraining triggers. The U.S. Food and Drug Administration provides guidance on Medical Device Reporting and Quality System Regulation Amendments, which can be found on their website, including 21 CFR Part 803 and Quality Management System Regulation.
Companies that get it right share one habit: the line between automation and judgment is written down, in a procedure, with names attached. Their validation file says what the tool does, and their monitoring data says it still works. When an investigator asks about AI, that is the whole conversation.
As companies implement AI-assisted triage, they should ensure that the tool is validated and monitored regularly.
Monitoring and Validation
This includes pulling a monthly sample of records the model scored as low priority and having a qualified reviewer re-read them without seeing the model’s score.
Companies should also track the model’s performance, measuring how reliably it flags records that were ultimately reportable, and watch that number over time. Defining retraining triggers, such as a new product launch or a shift in complaint language, is also key, as it forces a revalidation of the model.
And set the acceptance bar before go-live, not after. If the tool must catch every known reportable case in a challenge set before it touches live data, write that down and keep the test set. This ensures that the tool is working as intended and that human judgment is still involved in the decision-making process.
The U.S. Food and Drug Administration’s Compliance Program 7382.850 provides guidance on the inspection of medical device manufacturers, including the review of Medical Device Reporting and Quality System Regulation Amendments. Companies should be prepared to show how they know the tool works and who decided the event in question was not reportable.
